Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.68, $0.03 better than the analyst estimate of $1.65. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.71 billion.

Xarelto revenue $529 million, versus $564 million expected.

Imbruvica revenue $349 million, estimate at $313 million.

Guidance:

J&J now sees FY16 adjusted EPS of $6.68 - $6.73, versus an expected range of $6.63 - $6.73 prior and compared with the current consensus of $6.69. Sales guidance was maintained.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.